Biocept, Inc. (NASDAQ:BIOC)’s share price rose 6.6% on Friday . The company traded as high as $1.33 and last traded at $1.30, with a volume of 573,027 shares traded. The stock had previously closed at $1.22.

BIOC has been the topic of a number of recent analyst reports. ValuEngine downgraded shares of Biocept from a “sell” rating to a “strong sell” rating in a report on Friday. Zacks Investment Research upgraded shares of Biocept from a “hold” rating to a “buy” rating and set a $1.75 target price on the stock in a report on Friday, June 2nd. Finally, Westpark Capital restated an “outperform” rating on shares of Biocept in a report on Thursday, August 3rd. Two research analysts have rated the stock with a sell rating and three have issued a buy rating to the stock. The company presently has a consensus rating of “Hold” and an average target price of $2.25.

The firm has a 50-day moving average price of $1.31 and a 200 day moving average price of $1.63. The stock’s market cap is $39.33 million.

Biocept (NASDAQ:BIOC) last released its quarterly earnings results on Thursday, August 10th. The medical research company reported ($0.21) EPS for the quarter, missing analysts’ consensus estimates of ($0.20) by $0.01. The company had revenue of $1.28 million during the quarter, compared to analysts’ expectations of $1.23 million. Biocept had a negative net margin of 359.48% and a negative return on equity of 550.35%. Analysts anticipate that Biocept, Inc. will post ($0.79) EPS for the current year.

A number of large investors have recently added to or reduced their stakes in the stock. Creative Planning raised its stake in Biocept by 64,679.8% in the second quarter. Creative Planning now owns 246,811 shares of the medical research company’s stock worth $338,000 after buying an additional 246,430 shares during the last quarter. Vanguard Group Inc. raised its stake in shares of Biocept by 9.6% in the second quarter. Vanguard Group Inc. now owns 764,351 shares of the medical research company’s stock valued at $1,048,000 after buying an additional 66,746 shares in the last quarter. Finally, Intellectus Partners LLC raised its stake in shares of Biocept by 6,250.0% in the first quarter. Intellectus Partners LLC now owns 127,000 shares of the medical research company’s stock valued at $271,000 after buying an additional 125,000 shares in the last quarter. 6.92% of the stock is owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION NOTICE: “Biocept, Inc. (BIOC) Stock Price Up 6.6%” was originally reported by Daily Political and is the property of of Daily Political. If you are viewing this story on another site, it was stolen and republished in violation of international copyright and trademark law. The legal version of this story can be viewed at

About Biocept

Biocept, Inc is an early commercial-stage molecular oncology diagnostics company. The Company develops and commercializes circulating tumor cell (CTC) and circulating tumor deoxyribonucleic acid (ctDNA), assays utilizing a standard blood sample, or liquid biopsy. The Company’s Target-Selector offering is based on an internally developed, microfluidics-based CTC capture and analysis platform, with enabling features that change how CTC testing can be used by clinicians by providing biomarker detection and monitoring requiring only a standard blood sample.